Global Hepatitis A Vaccine review

Hepatitis A Vaccine Comprehensive Study by Type (Liver Inactivated Vaccine, Live Attenuated Vaccine), Application (Hospitals & Clinics,, Others (Organizations Associated with Government Vaccinations Programs)), Patient Type (Paediatrics, Adults), Route of Administration (Intramuscular and Subcutaneous Administration, Oral Administration, Other Routes of Administration) Players and Region - Global Market Outlook to 2026

Hepatitis A Vaccine Market by XX Submarkets | Forecast Years 2022-2027  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
Global Hepatitis A Vaccine Market Overview:
Hepatitis means inflammation of the liver which is caused by hepatitis A virus that can lead to mild to severe illness. The hepatitis A virus (HAV) is spread through direct contact with an infectious person or through ingestion of contaminated food and water. For instance, in low- and middle-income countries with poor sanitary conditions and hygienic practices, infection is common and most children (90%) have been infected with the hepatitis A virus before the age of 10 years, most often without symptoms.

Growth Drivers
  • Growing Government Support for Vaccine Development in Developing Economies
  • Increasing Prevalence of Infectious Diseases in Low and Middle Income Nations

Roadblocks
  • The High Cost of Vaccine Development

Opportunities
  • The rise in the Number of Hepatitis A Cases in Children
  • Continuous Focus by Governments and Health Care Organizations to Spread Awareness about the Disease

Challenges
  • Inadequate Access to Vaccines
  • Increasing Number of Product Recalls


Competitive Landscape:

Some of the key players profiled in the report are GlaxoSmithKline (United Kingdom), Merck & Co. (United States), SANOFI PASTEUR S.A (France), Norvatis (Switzerland), Johnson & Johnson (United States), China Academy of Medical Sciences (China), Sinovac Biotech Ltd. (China) and Walvax Biotechnology Co. (China). Considering Market by Patient Type, the sub-segment i.e. Paediatrics will boost the Hepatitis A Vaccine market. Considering Market by Route of Administration, the sub-segment i.e. Intramuscular and Subcutaneous Administration will boost the Hepatitis A Vaccine market.

What Can be Explored with the Hepatitis A Vaccine Market Study
 Gain Market Understanding
 Identify Growth Opportunities
 Analyze and Measure the Global Hepatitis A Vaccine Market by Identifying Investment across various Industry Verticals
 Understand the Trends that will drive Future Changes in Hepatitis A Vaccine
 Understand the Competitive Scenario
- Track Right Markets
- Identify the Right Verticals

Research Methodology:
The top-down and bottom-up approaches are used to estimate and validate the size of the Global Hepatitis A Vaccine market.
In order to reach an exhaustive list of functional and relevant players various industry classification standards are closely followed such as NAICS, ICB, SIC to penetrate deep in important geographies by players and a thorough validation test is conducted to reach most relevant players for survey in Hepatitis A Vaccine market.
In order to make priority list sorting is done based on revenue generated based on latest reporting with the help of paid databases such as Factiva, Bloomberg etc.
Finally the questionnaire is set and specifically designed to address all the necessities for primary data collection after getting prior appointment by targeting key target audience that includes Manufacturers and suppliers of vaccines, Research and development companies, Medical research laboratories and Academic medical centers and universities.
This helps us to gather the data related to players revenue, operating cycle and expense, profit along with product or service growth etc.
Almost 70-80% of data is collected through primary medium and further validation is done through various secondary sources that includes Regulators, World Bank, Association, Company Website, SEC filings, OTC BB, USPTO, EPO, Annual reports, press releases etc.

Report Objectives / Segmentation Covered

By Type
  • Liver Inactivated Vaccine
  • Live Attenuated Vaccine
By Application
  • Hospitals & Clinics,
  • Others (Organizations Associated with Government Vaccinations Programs)
By Patient Type
  • Paediatrics
  • Adults

By Route of Administration
  • Intramuscular and Subcutaneous Administration
  • Oral Administration
  • Other Routes of Administration

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Growing Government Support for Vaccine Development in Developing Economies
      • 3.2.2. Increasing Prevalence of Infectious Diseases in Low and Middle Income Nations
    • 3.3. Market Challenges
      • 3.3.1. Inadequate Access to Vaccines
      • 3.3.2. Increasing Number of Product Recalls
    • 3.4. Market Trends
      • 3.4.1. Initiatives to Enhance Vaccine R&D by Key Market Players
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Hepatitis A Vaccine, by Type, Application, Patient Type, Route of Administration and Region (value, volume and price ) (2015-2020)
    • 5.1. Introduction
    • 5.2. Global Hepatitis A Vaccine (Value)
      • 5.2.1. Global Hepatitis A Vaccine by: Type (Value)
        • 5.2.1.1. Liver Inactivated Vaccine
        • 5.2.1.2. Live Attenuated Vaccine
      • 5.2.2. Global Hepatitis A Vaccine by: Application (Value)
        • 5.2.2.1. Hospitals & Clinics,
        • 5.2.2.2. Others (Organizations Associated with Government Vaccinations Programs)
      • 5.2.3. Global Hepatitis A Vaccine by: Patient Type (Value)
        • 5.2.3.1. Paediatrics
        • 5.2.3.2. Adults
      • 5.2.4. Global Hepatitis A Vaccine by: Route of Administration (Value)
        • 5.2.4.1. Intramuscular and Subcutaneous Administration
        • 5.2.4.2. Oral Administration
        • 5.2.4.3. Other Routes of Administration
      • 5.2.5. Global Hepatitis A Vaccine Region
        • 5.2.5.1. South America
          • 5.2.5.1.1. Brazil
          • 5.2.5.1.2. Argentina
          • 5.2.5.1.3. Rest of South America
        • 5.2.5.2. Asia Pacific
          • 5.2.5.2.1. China
          • 5.2.5.2.2. Japan
          • 5.2.5.2.3. India
          • 5.2.5.2.4. South Korea
          • 5.2.5.2.5. Taiwan
          • 5.2.5.2.6. Australia
          • 5.2.5.2.7. Rest of Asia-Pacific
        • 5.2.5.3. Europe
          • 5.2.5.3.1. Germany
          • 5.2.5.3.2. France
          • 5.2.5.3.3. Italy
          • 5.2.5.3.4. United Kingdom
          • 5.2.5.3.5. Netherlands
          • 5.2.5.3.6. Rest of Europe
        • 5.2.5.4. MEA
          • 5.2.5.4.1. Middle East
          • 5.2.5.4.2. Africa
        • 5.2.5.5. North America
          • 5.2.5.5.1. United States
          • 5.2.5.5.2. Canada
          • 5.2.5.5.3. Mexico
    • 5.3. Global Hepatitis A Vaccine (Volume)
      • 5.3.1. Global Hepatitis A Vaccine by: Type (Volume)
        • 5.3.1.1. Liver Inactivated Vaccine
        • 5.3.1.2. Live Attenuated Vaccine
      • 5.3.2. Global Hepatitis A Vaccine by: Application (Volume)
        • 5.3.2.1. Hospitals & Clinics,
        • 5.3.2.2. Others (Organizations Associated with Government Vaccinations Programs)
      • 5.3.3. Global Hepatitis A Vaccine by: Patient Type (Volume)
        • 5.3.3.1. Paediatrics
        • 5.3.3.2. Adults
      • 5.3.4. Global Hepatitis A Vaccine by: Route of Administration (Volume)
        • 5.3.4.1. Intramuscular and Subcutaneous Administration
        • 5.3.4.2. Oral Administration
        • 5.3.4.3. Other Routes of Administration
      • 5.3.5. Global Hepatitis A Vaccine Region
        • 5.3.5.1. South America
          • 5.3.5.1.1. Brazil
          • 5.3.5.1.2. Argentina
          • 5.3.5.1.3. Rest of South America
        • 5.3.5.2. Asia Pacific
          • 5.3.5.2.1. China
          • 5.3.5.2.2. Japan
          • 5.3.5.2.3. India
          • 5.3.5.2.4. South Korea
          • 5.3.5.2.5. Taiwan
          • 5.3.5.2.6. Australia
          • 5.3.5.2.7. Rest of Asia-Pacific
        • 5.3.5.3. Europe
          • 5.3.5.3.1. Germany
          • 5.3.5.3.2. France
          • 5.3.5.3.3. Italy
          • 5.3.5.3.4. United Kingdom
          • 5.3.5.3.5. Netherlands
          • 5.3.5.3.6. Rest of Europe
        • 5.3.5.4. MEA
          • 5.3.5.4.1. Middle East
          • 5.3.5.4.2. Africa
        • 5.3.5.5. North America
          • 5.3.5.5.1. United States
          • 5.3.5.5.2. Canada
          • 5.3.5.5.3. Mexico
    • 5.4. Global Hepatitis A Vaccine (Price)
      • 5.4.1. Global Hepatitis A Vaccine by: Type (Price)
  • 6. Hepatitis A Vaccine: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2020)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. GlaxoSmithKline (United Kingdom)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Merck & Co. (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. SANOFI PASTEUR S.A (France)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Norvatis (Switzerland)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Johnson & Johnson (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. China Academy of Medical Sciences (China)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Sinovac Biotech Ltd. (China)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Walvax Biotechnology Co. (China)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
  • 7. Global Hepatitis A Vaccine Sale, by Type, Application, Patient Type, Route of Administration and Region (value, volume and price ) (2021-2026)
    • 7.1. Introduction
    • 7.2. Global Hepatitis A Vaccine (Value)
      • 7.2.1. Global Hepatitis A Vaccine by: Type (Value)
        • 7.2.1.1. Liver Inactivated Vaccine
        • 7.2.1.2. Live Attenuated Vaccine
      • 7.2.2. Global Hepatitis A Vaccine by: Application (Value)
        • 7.2.2.1. Hospitals & Clinics,
        • 7.2.2.2. Others (Organizations Associated with Government Vaccinations Programs)
      • 7.2.3. Global Hepatitis A Vaccine by: Patient Type (Value)
        • 7.2.3.1. Paediatrics
        • 7.2.3.2. Adults
      • 7.2.4. Global Hepatitis A Vaccine by: Route of Administration (Value)
        • 7.2.4.1. Intramuscular and Subcutaneous Administration
        • 7.2.4.2. Oral Administration
        • 7.2.4.3. Other Routes of Administration
      • 7.2.5. Global Hepatitis A Vaccine Region
        • 7.2.5.1. South America
          • 7.2.5.1.1. Brazil
          • 7.2.5.1.2. Argentina
          • 7.2.5.1.3. Rest of South America
        • 7.2.5.2. Asia Pacific
          • 7.2.5.2.1. China
          • 7.2.5.2.2. Japan
          • 7.2.5.2.3. India
          • 7.2.5.2.4. South Korea
          • 7.2.5.2.5. Taiwan
          • 7.2.5.2.6. Australia
          • 7.2.5.2.7. Rest of Asia-Pacific
        • 7.2.5.3. Europe
          • 7.2.5.3.1. Germany
          • 7.2.5.3.2. France
          • 7.2.5.3.3. Italy
          • 7.2.5.3.4. United Kingdom
          • 7.2.5.3.5. Netherlands
          • 7.2.5.3.6. Rest of Europe
        • 7.2.5.4. MEA
          • 7.2.5.4.1. Middle East
          • 7.2.5.4.2. Africa
        • 7.2.5.5. North America
          • 7.2.5.5.1. United States
          • 7.2.5.5.2. Canada
          • 7.2.5.5.3. Mexico
    • 7.3. Global Hepatitis A Vaccine (Volume)
      • 7.3.1. Global Hepatitis A Vaccine by: Type (Volume)
        • 7.3.1.1. Liver Inactivated Vaccine
        • 7.3.1.2. Live Attenuated Vaccine
      • 7.3.2. Global Hepatitis A Vaccine by: Application (Volume)
        • 7.3.2.1. Hospitals & Clinics,
        • 7.3.2.2. Others (Organizations Associated with Government Vaccinations Programs)
      • 7.3.3. Global Hepatitis A Vaccine by: Patient Type (Volume)
        • 7.3.3.1. Paediatrics
        • 7.3.3.2. Adults
      • 7.3.4. Global Hepatitis A Vaccine by: Route of Administration (Volume)
        • 7.3.4.1. Intramuscular and Subcutaneous Administration
        • 7.3.4.2. Oral Administration
        • 7.3.4.3. Other Routes of Administration
      • 7.3.5. Global Hepatitis A Vaccine Region
        • 7.3.5.1. South America
          • 7.3.5.1.1. Brazil
          • 7.3.5.1.2. Argentina
          • 7.3.5.1.3. Rest of South America
        • 7.3.5.2. Asia Pacific
          • 7.3.5.2.1. China
          • 7.3.5.2.2. Japan
          • 7.3.5.2.3. India
          • 7.3.5.2.4. South Korea
          • 7.3.5.2.5. Taiwan
          • 7.3.5.2.6. Australia
          • 7.3.5.2.7. Rest of Asia-Pacific
        • 7.3.5.3. Europe
          • 7.3.5.3.1. Germany
          • 7.3.5.3.2. France
          • 7.3.5.3.3. Italy
          • 7.3.5.3.4. United Kingdom
          • 7.3.5.3.5. Netherlands
          • 7.3.5.3.6. Rest of Europe
        • 7.3.5.4. MEA
          • 7.3.5.4.1. Middle East
          • 7.3.5.4.2. Africa
        • 7.3.5.5. North America
          • 7.3.5.5.1. United States
          • 7.3.5.5.2. Canada
          • 7.3.5.5.3. Mexico
    • 7.4. Global Hepatitis A Vaccine (Price)
      • 7.4.1. Global Hepatitis A Vaccine by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Hepatitis A Vaccine: by Type(USD Million)
  • Table 2. Hepatitis A Vaccine Liver Inactivated Vaccine , by Region USD Million (2015-2020)
  • Table 3. Hepatitis A Vaccine Live Attenuated Vaccine , by Region USD Million (2015-2020)
  • Table 4. Hepatitis A Vaccine: by Application(USD Million)
  • Table 5. Hepatitis A Vaccine Hospitals & Clinics, , by Region USD Million (2015-2020)
  • Table 6. Hepatitis A Vaccine Others (Organizations Associated with Government Vaccinations Programs) , by Region USD Million (2015-2020)
  • Table 7. Hepatitis A Vaccine: by Patient Type(USD Million)
  • Table 8. Hepatitis A Vaccine Paediatrics , by Region USD Million (2015-2020)
  • Table 9. Hepatitis A Vaccine Adults , by Region USD Million (2015-2020)
  • Table 10. Hepatitis A Vaccine: by Route of Administration(USD Million)
  • Table 11. Hepatitis A Vaccine Intramuscular and Subcutaneous Administration , by Region USD Million (2015-2020)
  • Table 12. Hepatitis A Vaccine Oral Administration , by Region USD Million (2015-2020)
  • Table 13. Hepatitis A Vaccine Other Routes of Administration , by Region USD Million (2015-2020)
  • Table 14. South America Hepatitis A Vaccine, by Country USD Million (2015-2020)
  • Table 15. South America Hepatitis A Vaccine, by Type USD Million (2015-2020)
  • Table 16. South America Hepatitis A Vaccine, by Application USD Million (2015-2020)
  • Table 17. South America Hepatitis A Vaccine, by Patient Type USD Million (2015-2020)
  • Table 18. South America Hepatitis A Vaccine, by Route of Administration USD Million (2015-2020)
  • Table 19. Brazil Hepatitis A Vaccine, by Type USD Million (2015-2020)
  • Table 20. Brazil Hepatitis A Vaccine, by Application USD Million (2015-2020)
  • Table 21. Brazil Hepatitis A Vaccine, by Patient Type USD Million (2015-2020)
  • Table 22. Brazil Hepatitis A Vaccine, by Route of Administration USD Million (2015-2020)
  • Table 23. Argentina Hepatitis A Vaccine, by Type USD Million (2015-2020)
  • Table 24. Argentina Hepatitis A Vaccine, by Application USD Million (2015-2020)
  • Table 25. Argentina Hepatitis A Vaccine, by Patient Type USD Million (2015-2020)
  • Table 26. Argentina Hepatitis A Vaccine, by Route of Administration USD Million (2015-2020)
  • Table 27. Rest of South America Hepatitis A Vaccine, by Type USD Million (2015-2020)
  • Table 28. Rest of South America Hepatitis A Vaccine, by Application USD Million (2015-2020)
  • Table 29. Rest of South America Hepatitis A Vaccine, by Patient Type USD Million (2015-2020)
  • Table 30. Rest of South America Hepatitis A Vaccine, by Route of Administration USD Million (2015-2020)
  • Table 31. Asia Pacific Hepatitis A Vaccine, by Country USD Million (2015-2020)
  • Table 32. Asia Pacific Hepatitis A Vaccine, by Type USD Million (2015-2020)
  • Table 33. Asia Pacific Hepatitis A Vaccine, by Application USD Million (2015-2020)
  • Table 34. Asia Pacific Hepatitis A Vaccine, by Patient Type USD Million (2015-2020)
  • Table 35. Asia Pacific Hepatitis A Vaccine, by Route of Administration USD Million (2015-2020)
  • Table 36. China Hepatitis A Vaccine, by Type USD Million (2015-2020)
  • Table 37. China Hepatitis A Vaccine, by Application USD Million (2015-2020)
  • Table 38. China Hepatitis A Vaccine, by Patient Type USD Million (2015-2020)
  • Table 39. China Hepatitis A Vaccine, by Route of Administration USD Million (2015-2020)
  • Table 40. Japan Hepatitis A Vaccine, by Type USD Million (2015-2020)
  • Table 41. Japan Hepatitis A Vaccine, by Application USD Million (2015-2020)
  • Table 42. Japan Hepatitis A Vaccine, by Patient Type USD Million (2015-2020)
  • Table 43. Japan Hepatitis A Vaccine, by Route of Administration USD Million (2015-2020)
  • Table 44. India Hepatitis A Vaccine, by Type USD Million (2015-2020)
  • Table 45. India Hepatitis A Vaccine, by Application USD Million (2015-2020)
  • Table 46. India Hepatitis A Vaccine, by Patient Type USD Million (2015-2020)
  • Table 47. India Hepatitis A Vaccine, by Route of Administration USD Million (2015-2020)
  • Table 48. South Korea Hepatitis A Vaccine, by Type USD Million (2015-2020)
  • Table 49. South Korea Hepatitis A Vaccine, by Application USD Million (2015-2020)
  • Table 50. South Korea Hepatitis A Vaccine, by Patient Type USD Million (2015-2020)
  • Table 51. South Korea Hepatitis A Vaccine, by Route of Administration USD Million (2015-2020)
  • Table 52. Taiwan Hepatitis A Vaccine, by Type USD Million (2015-2020)
  • Table 53. Taiwan Hepatitis A Vaccine, by Application USD Million (2015-2020)
  • Table 54. Taiwan Hepatitis A Vaccine, by Patient Type USD Million (2015-2020)
  • Table 55. Taiwan Hepatitis A Vaccine, by Route of Administration USD Million (2015-2020)
  • Table 56. Australia Hepatitis A Vaccine, by Type USD Million (2015-2020)
  • Table 57. Australia Hepatitis A Vaccine, by Application USD Million (2015-2020)
  • Table 58. Australia Hepatitis A Vaccine, by Patient Type USD Million (2015-2020)
  • Table 59. Australia Hepatitis A Vaccine, by Route of Administration USD Million (2015-2020)
  • Table 60. Rest of Asia-Pacific Hepatitis A Vaccine, by Type USD Million (2015-2020)
  • Table 61. Rest of Asia-Pacific Hepatitis A Vaccine, by Application USD Million (2015-2020)
  • Table 62. Rest of Asia-Pacific Hepatitis A Vaccine, by Patient Type USD Million (2015-2020)
  • Table 63. Rest of Asia-Pacific Hepatitis A Vaccine, by Route of Administration USD Million (2015-2020)
  • Table 64. Europe Hepatitis A Vaccine, by Country USD Million (2015-2020)
  • Table 65. Europe Hepatitis A Vaccine, by Type USD Million (2015-2020)
  • Table 66. Europe Hepatitis A Vaccine, by Application USD Million (2015-2020)
  • Table 67. Europe Hepatitis A Vaccine, by Patient Type USD Million (2015-2020)
  • Table 68. Europe Hepatitis A Vaccine, by Route of Administration USD Million (2015-2020)
  • Table 69. Germany Hepatitis A Vaccine, by Type USD Million (2015-2020)
  • Table 70. Germany Hepatitis A Vaccine, by Application USD Million (2015-2020)
  • Table 71. Germany Hepatitis A Vaccine, by Patient Type USD Million (2015-2020)
  • Table 72. Germany Hepatitis A Vaccine, by Route of Administration USD Million (2015-2020)
  • Table 73. France Hepatitis A Vaccine, by Type USD Million (2015-2020)
  • Table 74. France Hepatitis A Vaccine, by Application USD Million (2015-2020)
  • Table 75. France Hepatitis A Vaccine, by Patient Type USD Million (2015-2020)
  • Table 76. France Hepatitis A Vaccine, by Route of Administration USD Million (2015-2020)
  • Table 77. Italy Hepatitis A Vaccine, by Type USD Million (2015-2020)
  • Table 78. Italy Hepatitis A Vaccine, by Application USD Million (2015-2020)
  • Table 79. Italy Hepatitis A Vaccine, by Patient Type USD Million (2015-2020)
  • Table 80. Italy Hepatitis A Vaccine, by Route of Administration USD Million (2015-2020)
  • Table 81. United Kingdom Hepatitis A Vaccine, by Type USD Million (2015-2020)
  • Table 82. United Kingdom Hepatitis A Vaccine, by Application USD Million (2015-2020)
  • Table 83. United Kingdom Hepatitis A Vaccine, by Patient Type USD Million (2015-2020)
  • Table 84. United Kingdom Hepatitis A Vaccine, by Route of Administration USD Million (2015-2020)
  • Table 85. Netherlands Hepatitis A Vaccine, by Type USD Million (2015-2020)
  • Table 86. Netherlands Hepatitis A Vaccine, by Application USD Million (2015-2020)
  • Table 87. Netherlands Hepatitis A Vaccine, by Patient Type USD Million (2015-2020)
  • Table 88. Netherlands Hepatitis A Vaccine, by Route of Administration USD Million (2015-2020)
  • Table 89. Rest of Europe Hepatitis A Vaccine, by Type USD Million (2015-2020)
  • Table 90. Rest of Europe Hepatitis A Vaccine, by Application USD Million (2015-2020)
  • Table 91. Rest of Europe Hepatitis A Vaccine, by Patient Type USD Million (2015-2020)
  • Table 92. Rest of Europe Hepatitis A Vaccine, by Route of Administration USD Million (2015-2020)
  • Table 93. MEA Hepatitis A Vaccine, by Country USD Million (2015-2020)
  • Table 94. MEA Hepatitis A Vaccine, by Type USD Million (2015-2020)
  • Table 95. MEA Hepatitis A Vaccine, by Application USD Million (2015-2020)
  • Table 96. MEA Hepatitis A Vaccine, by Patient Type USD Million (2015-2020)
  • Table 97. MEA Hepatitis A Vaccine, by Route of Administration USD Million (2015-2020)
  • Table 98. Middle East Hepatitis A Vaccine, by Type USD Million (2015-2020)
  • Table 99. Middle East Hepatitis A Vaccine, by Application USD Million (2015-2020)
  • Table 100. Middle East Hepatitis A Vaccine, by Patient Type USD Million (2015-2020)
  • Table 101. Middle East Hepatitis A Vaccine, by Route of Administration USD Million (2015-2020)
  • Table 102. Africa Hepatitis A Vaccine, by Type USD Million (2015-2020)
  • Table 103. Africa Hepatitis A Vaccine, by Application USD Million (2015-2020)
  • Table 104. Africa Hepatitis A Vaccine, by Patient Type USD Million (2015-2020)
  • Table 105. Africa Hepatitis A Vaccine, by Route of Administration USD Million (2015-2020)
  • Table 106. North America Hepatitis A Vaccine, by Country USD Million (2015-2020)
  • Table 107. North America Hepatitis A Vaccine, by Type USD Million (2015-2020)
  • Table 108. North America Hepatitis A Vaccine, by Application USD Million (2015-2020)
  • Table 109. North America Hepatitis A Vaccine, by Patient Type USD Million (2015-2020)
  • Table 110. North America Hepatitis A Vaccine, by Route of Administration USD Million (2015-2020)
  • Table 111. United States Hepatitis A Vaccine, by Type USD Million (2015-2020)
  • Table 112. United States Hepatitis A Vaccine, by Application USD Million (2015-2020)
  • Table 113. United States Hepatitis A Vaccine, by Patient Type USD Million (2015-2020)
  • Table 114. United States Hepatitis A Vaccine, by Route of Administration USD Million (2015-2020)
  • Table 115. Canada Hepatitis A Vaccine, by Type USD Million (2015-2020)
  • Table 116. Canada Hepatitis A Vaccine, by Application USD Million (2015-2020)
  • Table 117. Canada Hepatitis A Vaccine, by Patient Type USD Million (2015-2020)
  • Table 118. Canada Hepatitis A Vaccine, by Route of Administration USD Million (2015-2020)
  • Table 119. Mexico Hepatitis A Vaccine, by Type USD Million (2015-2020)
  • Table 120. Mexico Hepatitis A Vaccine, by Application USD Million (2015-2020)
  • Table 121. Mexico Hepatitis A Vaccine, by Patient Type USD Million (2015-2020)
  • Table 122. Mexico Hepatitis A Vaccine, by Route of Administration USD Million (2015-2020)
  • Table 123. Hepatitis A Vaccine Sales: by Type(K Unit)
  • Table 124. Hepatitis A Vaccine Sales Liver Inactivated Vaccine , by Region K Unit (2015-2020)
  • Table 125. Hepatitis A Vaccine Sales Live Attenuated Vaccine , by Region K Unit (2015-2020)
  • Table 126. Hepatitis A Vaccine Sales: by Application(K Unit)
  • Table 127. Hepatitis A Vaccine Sales Hospitals & Clinics, , by Region K Unit (2015-2020)
  • Table 128. Hepatitis A Vaccine Sales Others (Organizations Associated with Government Vaccinations Programs) , by Region K Unit (2015-2020)
  • Table 129. Hepatitis A Vaccine Sales: by Patient Type(K Unit)
  • Table 130. Hepatitis A Vaccine Sales Paediatrics , by Region K Unit (2015-2020)
  • Table 131. Hepatitis A Vaccine Sales Adults , by Region K Unit (2015-2020)
  • Table 132. Hepatitis A Vaccine Sales: by Route of Administration(K Unit)
  • Table 133. Hepatitis A Vaccine Sales Intramuscular and Subcutaneous Administration , by Region K Unit (2015-2020)
  • Table 134. Hepatitis A Vaccine Sales Oral Administration , by Region K Unit (2015-2020)
  • Table 135. Hepatitis A Vaccine Sales Other Routes of Administration , by Region K Unit (2015-2020)
  • Table 136. South America Hepatitis A Vaccine Sales, by Country K Unit (2015-2020)
  • Table 137. South America Hepatitis A Vaccine Sales, by Type K Unit (2015-2020)
  • Table 138. South America Hepatitis A Vaccine Sales, by Application K Unit (2015-2020)
  • Table 139. South America Hepatitis A Vaccine Sales, by Patient Type K Unit (2015-2020)
  • Table 140. South America Hepatitis A Vaccine Sales, by Route of Administration K Unit (2015-2020)
  • Table 141. Brazil Hepatitis A Vaccine Sales, by Type K Unit (2015-2020)
  • Table 142. Brazil Hepatitis A Vaccine Sales, by Application K Unit (2015-2020)
  • Table 143. Brazil Hepatitis A Vaccine Sales, by Patient Type K Unit (2015-2020)
  • Table 144. Brazil Hepatitis A Vaccine Sales, by Route of Administration K Unit (2015-2020)
  • Table 145. Argentina Hepatitis A Vaccine Sales, by Type K Unit (2015-2020)
  • Table 146. Argentina Hepatitis A Vaccine Sales, by Application K Unit (2015-2020)
  • Table 147. Argentina Hepatitis A Vaccine Sales, by Patient Type K Unit (2015-2020)
  • Table 148. Argentina Hepatitis A Vaccine Sales, by Route of Administration K Unit (2015-2020)
  • Table 149. Rest of South America Hepatitis A Vaccine Sales, by Type K Unit (2015-2020)
  • Table 150. Rest of South America Hepatitis A Vaccine Sales, by Application K Unit (2015-2020)
  • Table 151. Rest of South America Hepatitis A Vaccine Sales, by Patient Type K Unit (2015-2020)
  • Table 152. Rest of South America Hepatitis A Vaccine Sales, by Route of Administration K Unit (2015-2020)
  • Table 153. Asia Pacific Hepatitis A Vaccine Sales, by Country K Unit (2015-2020)
  • Table 154. Asia Pacific Hepatitis A Vaccine Sales, by Type K Unit (2015-2020)
  • Table 155. Asia Pacific Hepatitis A Vaccine Sales, by Application K Unit (2015-2020)
  • Table 156. Asia Pacific Hepatitis A Vaccine Sales, by Patient Type K Unit (2015-2020)
  • Table 157. Asia Pacific Hepatitis A Vaccine Sales, by Route of Administration K Unit (2015-2020)
  • Table 158. China Hepatitis A Vaccine Sales, by Type K Unit (2015-2020)
  • Table 159. China Hepatitis A Vaccine Sales, by Application K Unit (2015-2020)
  • Table 160. China Hepatitis A Vaccine Sales, by Patient Type K Unit (2015-2020)
  • Table 161. China Hepatitis A Vaccine Sales, by Route of Administration K Unit (2015-2020)
  • Table 162. Japan Hepatitis A Vaccine Sales, by Type K Unit (2015-2020)
  • Table 163. Japan Hepatitis A Vaccine Sales, by Application K Unit (2015-2020)
  • Table 164. Japan Hepatitis A Vaccine Sales, by Patient Type K Unit (2015-2020)
  • Table 165. Japan Hepatitis A Vaccine Sales, by Route of Administration K Unit (2015-2020)
  • Table 166. India Hepatitis A Vaccine Sales, by Type K Unit (2015-2020)
  • Table 167. India Hepatitis A Vaccine Sales, by Application K Unit (2015-2020)
  • Table 168. India Hepatitis A Vaccine Sales, by Patient Type K Unit (2015-2020)
  • Table 169. India Hepatitis A Vaccine Sales, by Route of Administration K Unit (2015-2020)
  • Table 170. South Korea Hepatitis A Vaccine Sales, by Type K Unit (2015-2020)
  • Table 171. South Korea Hepatitis A Vaccine Sales, by Application K Unit (2015-2020)
  • Table 172. South Korea Hepatitis A Vaccine Sales, by Patient Type K Unit (2015-2020)
  • Table 173. South Korea Hepatitis A Vaccine Sales, by Route of Administration K Unit (2015-2020)
  • Table 174. Taiwan Hepatitis A Vaccine Sales, by Type K Unit (2015-2020)
  • Table 175. Taiwan Hepatitis A Vaccine Sales, by Application K Unit (2015-2020)
  • Table 176. Taiwan Hepatitis A Vaccine Sales, by Patient Type K Unit (2015-2020)
  • Table 177. Taiwan Hepatitis A Vaccine Sales, by Route of Administration K Unit (2015-2020)
  • Table 178. Australia Hepatitis A Vaccine Sales, by Type K Unit (2015-2020)
  • Table 179. Australia Hepatitis A Vaccine Sales, by Application K Unit (2015-2020)
  • Table 180. Australia Hepatitis A Vaccine Sales, by Patient Type K Unit (2015-2020)
  • Table 181. Australia Hepatitis A Vaccine Sales, by Route of Administration K Unit (2015-2020)
  • Table 182. Rest of Asia-Pacific Hepatitis A Vaccine Sales, by Type K Unit (2015-2020)
  • Table 183. Rest of Asia-Pacific Hepatitis A Vaccine Sales, by Application K Unit (2015-2020)
  • Table 184. Rest of Asia-Pacific Hepatitis A Vaccine Sales, by Patient Type K Unit (2015-2020)
  • Table 185. Rest of Asia-Pacific Hepatitis A Vaccine Sales, by Route of Administration K Unit (2015-2020)
  • Table 186. Europe Hepatitis A Vaccine Sales, by Country K Unit (2015-2020)
  • Table 187. Europe Hepatitis A Vaccine Sales, by Type K Unit (2015-2020)
  • Table 188. Europe Hepatitis A Vaccine Sales, by Application K Unit (2015-2020)
  • Table 189. Europe Hepatitis A Vaccine Sales, by Patient Type K Unit (2015-2020)
  • Table 190. Europe Hepatitis A Vaccine Sales, by Route of Administration K Unit (2015-2020)
  • Table 191. Germany Hepatitis A Vaccine Sales, by Type K Unit (2015-2020)
  • Table 192. Germany Hepatitis A Vaccine Sales, by Application K Unit (2015-2020)
  • Table 193. Germany Hepatitis A Vaccine Sales, by Patient Type K Unit (2015-2020)
  • Table 194. Germany Hepatitis A Vaccine Sales, by Route of Administration K Unit (2015-2020)
  • Table 195. France Hepatitis A Vaccine Sales, by Type K Unit (2015-2020)
  • Table 196. France Hepatitis A Vaccine Sales, by Application K Unit (2015-2020)
  • Table 197. France Hepatitis A Vaccine Sales, by Patient Type K Unit (2015-2020)
  • Table 198. France Hepatitis A Vaccine Sales, by Route of Administration K Unit (2015-2020)
  • Table 199. Italy Hepatitis A Vaccine Sales, by Type K Unit (2015-2020)
  • Table 200. Italy Hepatitis A Vaccine Sales, by Application K Unit (2015-2020)
  • Table 201. Italy Hepatitis A Vaccine Sales, by Patient Type K Unit (2015-2020)
  • Table 202. Italy Hepatitis A Vaccine Sales, by Route of Administration K Unit (2015-2020)
  • Table 203. United Kingdom Hepatitis A Vaccine Sales, by Type K Unit (2015-2020)
  • Table 204. United Kingdom Hepatitis A Vaccine Sales, by Application K Unit (2015-2020)
  • Table 205. United Kingdom Hepatitis A Vaccine Sales, by Patient Type K Unit (2015-2020)
  • Table 206. United Kingdom Hepatitis A Vaccine Sales, by Route of Administration K Unit (2015-2020)
  • Table 207. Netherlands Hepatitis A Vaccine Sales, by Type K Unit (2015-2020)
  • Table 208. Netherlands Hepatitis A Vaccine Sales, by Application K Unit (2015-2020)
  • Table 209. Netherlands Hepatitis A Vaccine Sales, by Patient Type K Unit (2015-2020)
  • Table 210. Netherlands Hepatitis A Vaccine Sales, by Route of Administration K Unit (2015-2020)
  • Table 211. Rest of Europe Hepatitis A Vaccine Sales, by Type K Unit (2015-2020)
  • Table 212. Rest of Europe Hepatitis A Vaccine Sales, by Application K Unit (2015-2020)
  • Table 213. Rest of Europe Hepatitis A Vaccine Sales, by Patient Type K Unit (2015-2020)
  • Table 214. Rest of Europe Hepatitis A Vaccine Sales, by Route of Administration K Unit (2015-2020)
  • Table 215. MEA Hepatitis A Vaccine Sales, by Country K Unit (2015-2020)
  • Table 216. MEA Hepatitis A Vaccine Sales, by Type K Unit (2015-2020)
  • Table 217. MEA Hepatitis A Vaccine Sales, by Application K Unit (2015-2020)
  • Table 218. MEA Hepatitis A Vaccine Sales, by Patient Type K Unit (2015-2020)
  • Table 219. MEA Hepatitis A Vaccine Sales, by Route of Administration K Unit (2015-2020)
  • Table 220. Middle East Hepatitis A Vaccine Sales, by Type K Unit (2015-2020)
  • Table 221. Middle East Hepatitis A Vaccine Sales, by Application K Unit (2015-2020)
  • Table 222. Middle East Hepatitis A Vaccine Sales, by Patient Type K Unit (2015-2020)
  • Table 223. Middle East Hepatitis A Vaccine Sales, by Route of Administration K Unit (2015-2020)
  • Table 224. Africa Hepatitis A Vaccine Sales, by Type K Unit (2015-2020)
  • Table 225. Africa Hepatitis A Vaccine Sales, by Application K Unit (2015-2020)
  • Table 226. Africa Hepatitis A Vaccine Sales, by Patient Type K Unit (2015-2020)
  • Table 227. Africa Hepatitis A Vaccine Sales, by Route of Administration K Unit (2015-2020)
  • Table 228. North America Hepatitis A Vaccine Sales, by Country K Unit (2015-2020)
  • Table 229. North America Hepatitis A Vaccine Sales, by Type K Unit (2015-2020)
  • Table 230. North America Hepatitis A Vaccine Sales, by Application K Unit (2015-2020)
  • Table 231. North America Hepatitis A Vaccine Sales, by Patient Type K Unit (2015-2020)
  • Table 232. North America Hepatitis A Vaccine Sales, by Route of Administration K Unit (2015-2020)
  • Table 233. United States Hepatitis A Vaccine Sales, by Type K Unit (2015-2020)
  • Table 234. United States Hepatitis A Vaccine Sales, by Application K Unit (2015-2020)
  • Table 235. United States Hepatitis A Vaccine Sales, by Patient Type K Unit (2015-2020)
  • Table 236. United States Hepatitis A Vaccine Sales, by Route of Administration K Unit (2015-2020)
  • Table 237. Canada Hepatitis A Vaccine Sales, by Type K Unit (2015-2020)
  • Table 238. Canada Hepatitis A Vaccine Sales, by Application K Unit (2015-2020)
  • Table 239. Canada Hepatitis A Vaccine Sales, by Patient Type K Unit (2015-2020)
  • Table 240. Canada Hepatitis A Vaccine Sales, by Route of Administration K Unit (2015-2020)
  • Table 241. Mexico Hepatitis A Vaccine Sales, by Type K Unit (2015-2020)
  • Table 242. Mexico Hepatitis A Vaccine Sales, by Application K Unit (2015-2020)
  • Table 243. Mexico Hepatitis A Vaccine Sales, by Patient Type K Unit (2015-2020)
  • Table 244. Mexico Hepatitis A Vaccine Sales, by Route of Administration K Unit (2015-2020)
  • Table 245. Hepatitis A Vaccine: by Type(USD/Units)
  • Table 246. Company Basic Information, Sales Area and Its Competitors
  • Table 247. Company Basic Information, Sales Area and Its Competitors
  • Table 248. Company Basic Information, Sales Area and Its Competitors
  • Table 249. Company Basic Information, Sales Area and Its Competitors
  • Table 250. Company Basic Information, Sales Area and Its Competitors
  • Table 251. Company Basic Information, Sales Area and Its Competitors
  • Table 252. Company Basic Information, Sales Area and Its Competitors
  • Table 253. Company Basic Information, Sales Area and Its Competitors
  • Table 254. Hepatitis A Vaccine: by Type(USD Million)
  • Table 255. Hepatitis A Vaccine Liver Inactivated Vaccine , by Region USD Million (2021-2026)
  • Table 256. Hepatitis A Vaccine Live Attenuated Vaccine , by Region USD Million (2021-2026)
  • Table 257. Hepatitis A Vaccine: by Application(USD Million)
  • Table 258. Hepatitis A Vaccine Hospitals & Clinics, , by Region USD Million (2021-2026)
  • Table 259. Hepatitis A Vaccine Others (Organizations Associated with Government Vaccinations Programs) , by Region USD Million (2021-2026)
  • Table 260. Hepatitis A Vaccine: by Patient Type(USD Million)
  • Table 261. Hepatitis A Vaccine Paediatrics , by Region USD Million (2021-2026)
  • Table 262. Hepatitis A Vaccine Adults , by Region USD Million (2021-2026)
  • Table 263. Hepatitis A Vaccine: by Route of Administration(USD Million)
  • Table 264. Hepatitis A Vaccine Intramuscular and Subcutaneous Administration , by Region USD Million (2021-2026)
  • Table 265. Hepatitis A Vaccine Oral Administration , by Region USD Million (2021-2026)
  • Table 266. Hepatitis A Vaccine Other Routes of Administration , by Region USD Million (2021-2026)
  • Table 267. South America Hepatitis A Vaccine, by Country USD Million (2021-2026)
  • Table 268. South America Hepatitis A Vaccine, by Type USD Million (2021-2026)
  • Table 269. South America Hepatitis A Vaccine, by Application USD Million (2021-2026)
  • Table 270. South America Hepatitis A Vaccine, by Patient Type USD Million (2021-2026)
  • Table 271. South America Hepatitis A Vaccine, by Route of Administration USD Million (2021-2026)
  • Table 272. Brazil Hepatitis A Vaccine, by Type USD Million (2021-2026)
  • Table 273. Brazil Hepatitis A Vaccine, by Application USD Million (2021-2026)
  • Table 274. Brazil Hepatitis A Vaccine, by Patient Type USD Million (2021-2026)
  • Table 275. Brazil Hepatitis A Vaccine, by Route of Administration USD Million (2021-2026)
  • Table 276. Argentina Hepatitis A Vaccine, by Type USD Million (2021-2026)
  • Table 277. Argentina Hepatitis A Vaccine, by Application USD Million (2021-2026)
  • Table 278. Argentina Hepatitis A Vaccine, by Patient Type USD Million (2021-2026)
  • Table 279. Argentina Hepatitis A Vaccine, by Route of Administration USD Million (2021-2026)
  • Table 280. Rest of South America Hepatitis A Vaccine, by Type USD Million (2021-2026)
  • Table 281. Rest of South America Hepatitis A Vaccine, by Application USD Million (2021-2026)
  • Table 282. Rest of South America Hepatitis A Vaccine, by Patient Type USD Million (2021-2026)
  • Table 283. Rest of South America Hepatitis A Vaccine, by Route of Administration USD Million (2021-2026)
  • Table 284. Asia Pacific Hepatitis A Vaccine, by Country USD Million (2021-2026)
  • Table 285. Asia Pacific Hepatitis A Vaccine, by Type USD Million (2021-2026)
  • Table 286. Asia Pacific Hepatitis A Vaccine, by Application USD Million (2021-2026)
  • Table 287. Asia Pacific Hepatitis A Vaccine, by Patient Type USD Million (2021-2026)
  • Table 288. Asia Pacific Hepatitis A Vaccine, by Route of Administration USD Million (2021-2026)
  • Table 289. China Hepatitis A Vaccine, by Type USD Million (2021-2026)
  • Table 290. China Hepatitis A Vaccine, by Application USD Million (2021-2026)
  • Table 291. China Hepatitis A Vaccine, by Patient Type USD Million (2021-2026)
  • Table 292. China Hepatitis A Vaccine, by Route of Administration USD Million (2021-2026)
  • Table 293. Japan Hepatitis A Vaccine, by Type USD Million (2021-2026)
  • Table 294. Japan Hepatitis A Vaccine, by Application USD Million (2021-2026)
  • Table 295. Japan Hepatitis A Vaccine, by Patient Type USD Million (2021-2026)
  • Table 296. Japan Hepatitis A Vaccine, by Route of Administration USD Million (2021-2026)
  • Table 297. India Hepatitis A Vaccine, by Type USD Million (2021-2026)
  • Table 298. India Hepatitis A Vaccine, by Application USD Million (2021-2026)
  • Table 299. India Hepatitis A Vaccine, by Patient Type USD Million (2021-2026)
  • Table 300. India Hepatitis A Vaccine, by Route of Administration USD Million (2021-2026)
  • Table 301. South Korea Hepatitis A Vaccine, by Type USD Million (2021-2026)
  • Table 302. South Korea Hepatitis A Vaccine, by Application USD Million (2021-2026)
  • Table 303. South Korea Hepatitis A Vaccine, by Patient Type USD Million (2021-2026)
  • Table 304. South Korea Hepatitis A Vaccine, by Route of Administration USD Million (2021-2026)
  • Table 305. Taiwan Hepatitis A Vaccine, by Type USD Million (2021-2026)
  • Table 306. Taiwan Hepatitis A Vaccine, by Application USD Million (2021-2026)
  • Table 307. Taiwan Hepatitis A Vaccine, by Patient Type USD Million (2021-2026)
  • Table 308. Taiwan Hepatitis A Vaccine, by Route of Administration USD Million (2021-2026)
  • Table 309. Australia Hepatitis A Vaccine, by Type USD Million (2021-2026)
  • Table 310. Australia Hepatitis A Vaccine, by Application USD Million (2021-2026)
  • Table 311. Australia Hepatitis A Vaccine, by Patient Type USD Million (2021-2026)
  • Table 312. Australia Hepatitis A Vaccine, by Route of Administration USD Million (2021-2026)
  • Table 313. Rest of Asia-Pacific Hepatitis A Vaccine, by Type USD Million (2021-2026)
  • Table 314. Rest of Asia-Pacific Hepatitis A Vaccine, by Application USD Million (2021-2026)
  • Table 315. Rest of Asia-Pacific Hepatitis A Vaccine, by Patient Type USD Million (2021-2026)
  • Table 316. Rest of Asia-Pacific Hepatitis A Vaccine, by Route of Administration USD Million (2021-2026)
  • Table 317. Europe Hepatitis A Vaccine, by Country USD Million (2021-2026)
  • Table 318. Europe Hepatitis A Vaccine, by Type USD Million (2021-2026)
  • Table 319. Europe Hepatitis A Vaccine, by Application USD Million (2021-2026)
  • Table 320. Europe Hepatitis A Vaccine, by Patient Type USD Million (2021-2026)
  • Table 321. Europe Hepatitis A Vaccine, by Route of Administration USD Million (2021-2026)
  • Table 322. Germany Hepatitis A Vaccine, by Type USD Million (2021-2026)
  • Table 323. Germany Hepatitis A Vaccine, by Application USD Million (2021-2026)
  • Table 324. Germany Hepatitis A Vaccine, by Patient Type USD Million (2021-2026)
  • Table 325. Germany Hepatitis A Vaccine, by Route of Administration USD Million (2021-2026)
  • Table 326. France Hepatitis A Vaccine, by Type USD Million (2021-2026)
  • Table 327. France Hepatitis A Vaccine, by Application USD Million (2021-2026)
  • Table 328. France Hepatitis A Vaccine, by Patient Type USD Million (2021-2026)
  • Table 329. France Hepatitis A Vaccine, by Route of Administration USD Million (2021-2026)
  • Table 330. Italy Hepatitis A Vaccine, by Type USD Million (2021-2026)
  • Table 331. Italy Hepatitis A Vaccine, by Application USD Million (2021-2026)
  • Table 332. Italy Hepatitis A Vaccine, by Patient Type USD Million (2021-2026)
  • Table 333. Italy Hepatitis A Vaccine, by Route of Administration USD Million (2021-2026)
  • Table 334. United Kingdom Hepatitis A Vaccine, by Type USD Million (2021-2026)
  • Table 335. United Kingdom Hepatitis A Vaccine, by Application USD Million (2021-2026)
  • Table 336. United Kingdom Hepatitis A Vaccine, by Patient Type USD Million (2021-2026)
  • Table 337. United Kingdom Hepatitis A Vaccine, by Route of Administration USD Million (2021-2026)
  • Table 338. Netherlands Hepatitis A Vaccine, by Type USD Million (2021-2026)
  • Table 339. Netherlands Hepatitis A Vaccine, by Application USD Million (2021-2026)
  • Table 340. Netherlands Hepatitis A Vaccine, by Patient Type USD Million (2021-2026)
  • Table 341. Netherlands Hepatitis A Vaccine, by Route of Administration USD Million (2021-2026)
  • Table 342. Rest of Europe Hepatitis A Vaccine, by Type USD Million (2021-2026)
  • Table 343. Rest of Europe Hepatitis A Vaccine, by Application USD Million (2021-2026)
  • Table 344. Rest of Europe Hepatitis A Vaccine, by Patient Type USD Million (2021-2026)
  • Table 345. Rest of Europe Hepatitis A Vaccine, by Route of Administration USD Million (2021-2026)
  • Table 346. MEA Hepatitis A Vaccine, by Country USD Million (2021-2026)
  • Table 347. MEA Hepatitis A Vaccine, by Type USD Million (2021-2026)
  • Table 348. MEA Hepatitis A Vaccine, by Application USD Million (2021-2026)
  • Table 349. MEA Hepatitis A Vaccine, by Patient Type USD Million (2021-2026)
  • Table 350. MEA Hepatitis A Vaccine, by Route of Administration USD Million (2021-2026)
  • Table 351. Middle East Hepatitis A Vaccine, by Type USD Million (2021-2026)
  • Table 352. Middle East Hepatitis A Vaccine, by Application USD Million (2021-2026)
  • Table 353. Middle East Hepatitis A Vaccine, by Patient Type USD Million (2021-2026)
  • Table 354. Middle East Hepatitis A Vaccine, by Route of Administration USD Million (2021-2026)
  • Table 355. Africa Hepatitis A Vaccine, by Type USD Million (2021-2026)
  • Table 356. Africa Hepatitis A Vaccine, by Application USD Million (2021-2026)
  • Table 357. Africa Hepatitis A Vaccine, by Patient Type USD Million (2021-2026)
  • Table 358. Africa Hepatitis A Vaccine, by Route of Administration USD Million (2021-2026)
  • Table 359. North America Hepatitis A Vaccine, by Country USD Million (2021-2026)
  • Table 360. North America Hepatitis A Vaccine, by Type USD Million (2021-2026)
  • Table 361. North America Hepatitis A Vaccine, by Application USD Million (2021-2026)
  • Table 362. North America Hepatitis A Vaccine, by Patient Type USD Million (2021-2026)
  • Table 363. North America Hepatitis A Vaccine, by Route of Administration USD Million (2021-2026)
  • Table 364. United States Hepatitis A Vaccine, by Type USD Million (2021-2026)
  • Table 365. United States Hepatitis A Vaccine, by Application USD Million (2021-2026)
  • Table 366. United States Hepatitis A Vaccine, by Patient Type USD Million (2021-2026)
  • Table 367. United States Hepatitis A Vaccine, by Route of Administration USD Million (2021-2026)
  • Table 368. Canada Hepatitis A Vaccine, by Type USD Million (2021-2026)
  • Table 369. Canada Hepatitis A Vaccine, by Application USD Million (2021-2026)
  • Table 370. Canada Hepatitis A Vaccine, by Patient Type USD Million (2021-2026)
  • Table 371. Canada Hepatitis A Vaccine, by Route of Administration USD Million (2021-2026)
  • Table 372. Mexico Hepatitis A Vaccine, by Type USD Million (2021-2026)
  • Table 373. Mexico Hepatitis A Vaccine, by Application USD Million (2021-2026)
  • Table 374. Mexico Hepatitis A Vaccine, by Patient Type USD Million (2021-2026)
  • Table 375. Mexico Hepatitis A Vaccine, by Route of Administration USD Million (2021-2026)
  • Table 376. Hepatitis A Vaccine Sales: by Type(K Unit)
  • Table 377. Hepatitis A Vaccine Sales Liver Inactivated Vaccine , by Region K Unit (2021-2026)
  • Table 378. Hepatitis A Vaccine Sales Live Attenuated Vaccine , by Region K Unit (2021-2026)
  • Table 379. Hepatitis A Vaccine Sales: by Application(K Unit)
  • Table 380. Hepatitis A Vaccine Sales Hospitals & Clinics, , by Region K Unit (2021-2026)
  • Table 381. Hepatitis A Vaccine Sales Others (Organizations Associated with Government Vaccinations Programs) , by Region K Unit (2021-2026)
  • Table 382. Hepatitis A Vaccine Sales: by Patient Type(K Unit)
  • Table 383. Hepatitis A Vaccine Sales Paediatrics , by Region K Unit (2021-2026)
  • Table 384. Hepatitis A Vaccine Sales Adults , by Region K Unit (2021-2026)
  • Table 385. Hepatitis A Vaccine Sales: by Route of Administration(K Unit)
  • Table 386. Hepatitis A Vaccine Sales Intramuscular and Subcutaneous Administration , by Region K Unit (2021-2026)
  • Table 387. Hepatitis A Vaccine Sales Oral Administration , by Region K Unit (2021-2026)
  • Table 388. Hepatitis A Vaccine Sales Other Routes of Administration , by Region K Unit (2021-2026)
  • Table 389. South America Hepatitis A Vaccine Sales, by Country K Unit (2021-2026)
  • Table 390. South America Hepatitis A Vaccine Sales, by Type K Unit (2021-2026)
  • Table 391. South America Hepatitis A Vaccine Sales, by Application K Unit (2021-2026)
  • Table 392. South America Hepatitis A Vaccine Sales, by Patient Type K Unit (2021-2026)
  • Table 393. South America Hepatitis A Vaccine Sales, by Route of Administration K Unit (2021-2026)
  • Table 394. Brazil Hepatitis A Vaccine Sales, by Type K Unit (2021-2026)
  • Table 395. Brazil Hepatitis A Vaccine Sales, by Application K Unit (2021-2026)
  • Table 396. Brazil Hepatitis A Vaccine Sales, by Patient Type K Unit (2021-2026)
  • Table 397. Brazil Hepatitis A Vaccine Sales, by Route of Administration K Unit (2021-2026)
  • Table 398. Argentina Hepatitis A Vaccine Sales, by Type K Unit (2021-2026)
  • Table 399. Argentina Hepatitis A Vaccine Sales, by Application K Unit (2021-2026)
  • Table 400. Argentina Hepatitis A Vaccine Sales, by Patient Type K Unit (2021-2026)
  • Table 401. Argentina Hepatitis A Vaccine Sales, by Route of Administration K Unit (2021-2026)
  • Table 402. Rest of South America Hepatitis A Vaccine Sales, by Type K Unit (2021-2026)
  • Table 403. Rest of South America Hepatitis A Vaccine Sales, by Application K Unit (2021-2026)
  • Table 404. Rest of South America Hepatitis A Vaccine Sales, by Patient Type K Unit (2021-2026)
  • Table 405. Rest of South America Hepatitis A Vaccine Sales, by Route of Administration K Unit (2021-2026)
  • Table 406. Asia Pacific Hepatitis A Vaccine Sales, by Country K Unit (2021-2026)
  • Table 407. Asia Pacific Hepatitis A Vaccine Sales, by Type K Unit (2021-2026)
  • Table 408. Asia Pacific Hepatitis A Vaccine Sales, by Application K Unit (2021-2026)
  • Table 409. Asia Pacific Hepatitis A Vaccine Sales, by Patient Type K Unit (2021-2026)
  • Table 410. Asia Pacific Hepatitis A Vaccine Sales, by Route of Administration K Unit (2021-2026)
  • Table 411. China Hepatitis A Vaccine Sales, by Type K Unit (2021-2026)
  • Table 412. China Hepatitis A Vaccine Sales, by Application K Unit (2021-2026)
  • Table 413. China Hepatitis A Vaccine Sales, by Patient Type K Unit (2021-2026)
  • Table 414. China Hepatitis A Vaccine Sales, by Route of Administration K Unit (2021-2026)
  • Table 415. Japan Hepatitis A Vaccine Sales, by Type K Unit (2021-2026)
  • Table 416. Japan Hepatitis A Vaccine Sales, by Application K Unit (2021-2026)
  • Table 417. Japan Hepatitis A Vaccine Sales, by Patient Type K Unit (2021-2026)
  • Table 418. Japan Hepatitis A Vaccine Sales, by Route of Administration K Unit (2021-2026)
  • Table 419. India Hepatitis A Vaccine Sales, by Type K Unit (2021-2026)
  • Table 420. India Hepatitis A Vaccine Sales, by Application K Unit (2021-2026)
  • Table 421. India Hepatitis A Vaccine Sales, by Patient Type K Unit (2021-2026)
  • Table 422. India Hepatitis A Vaccine Sales, by Route of Administration K Unit (2021-2026)
  • Table 423. South Korea Hepatitis A Vaccine Sales, by Type K Unit (2021-2026)
  • Table 424. South Korea Hepatitis A Vaccine Sales, by Application K Unit (2021-2026)
  • Table 425. South Korea Hepatitis A Vaccine Sales, by Patient Type K Unit (2021-2026)
  • Table 426. South Korea Hepatitis A Vaccine Sales, by Route of Administration K Unit (2021-2026)
  • Table 427. Taiwan Hepatitis A Vaccine Sales, by Type K Unit (2021-2026)
  • Table 428. Taiwan Hepatitis A Vaccine Sales, by Application K Unit (2021-2026)
  • Table 429. Taiwan Hepatitis A Vaccine Sales, by Patient Type K Unit (2021-2026)
  • Table 430. Taiwan Hepatitis A Vaccine Sales, by Route of Administration K Unit (2021-2026)
  • Table 431. Australia Hepatitis A Vaccine Sales, by Type K Unit (2021-2026)
  • Table 432. Australia Hepatitis A Vaccine Sales, by Application K Unit (2021-2026)
  • Table 433. Australia Hepatitis A Vaccine Sales, by Patient Type K Unit (2021-2026)
  • Table 434. Australia Hepatitis A Vaccine Sales, by Route of Administration K Unit (2021-2026)
  • Table 435. Rest of Asia-Pacific Hepatitis A Vaccine Sales, by Type K Unit (2021-2026)
  • Table 436. Rest of Asia-Pacific Hepatitis A Vaccine Sales, by Application K Unit (2021-2026)
  • Table 437. Rest of Asia-Pacific Hepatitis A Vaccine Sales, by Patient Type K Unit (2021-2026)
  • Table 438. Rest of Asia-Pacific Hepatitis A Vaccine Sales, by Route of Administration K Unit (2021-2026)
  • Table 439. Europe Hepatitis A Vaccine Sales, by Country K Unit (2021-2026)
  • Table 440. Europe Hepatitis A Vaccine Sales, by Type K Unit (2021-2026)
  • Table 441. Europe Hepatitis A Vaccine Sales, by Application K Unit (2021-2026)
  • Table 442. Europe Hepatitis A Vaccine Sales, by Patient Type K Unit (2021-2026)
  • Table 443. Europe Hepatitis A Vaccine Sales, by Route of Administration K Unit (2021-2026)
  • Table 444. Germany Hepatitis A Vaccine Sales, by Type K Unit (2021-2026)
  • Table 445. Germany Hepatitis A Vaccine Sales, by Application K Unit (2021-2026)
  • Table 446. Germany Hepatitis A Vaccine Sales, by Patient Type K Unit (2021-2026)
  • Table 447. Germany Hepatitis A Vaccine Sales, by Route of Administration K Unit (2021-2026)
  • Table 448. France Hepatitis A Vaccine Sales, by Type K Unit (2021-2026)
  • Table 449. France Hepatitis A Vaccine Sales, by Application K Unit (2021-2026)
  • Table 450. France Hepatitis A Vaccine Sales, by Patient Type K Unit (2021-2026)
  • Table 451. France Hepatitis A Vaccine Sales, by Route of Administration K Unit (2021-2026)
  • Table 452. Italy Hepatitis A Vaccine Sales, by Type K Unit (2021-2026)
  • Table 453. Italy Hepatitis A Vaccine Sales, by Application K Unit (2021-2026)
  • Table 454. Italy Hepatitis A Vaccine Sales, by Patient Type K Unit (2021-2026)
  • Table 455. Italy Hepatitis A Vaccine Sales, by Route of Administration K Unit (2021-2026)
  • Table 456. United Kingdom Hepatitis A Vaccine Sales, by Type K Unit (2021-2026)
  • Table 457. United Kingdom Hepatitis A Vaccine Sales, by Application K Unit (2021-2026)
  • Table 458. United Kingdom Hepatitis A Vaccine Sales, by Patient Type K Unit (2021-2026)
  • Table 459. United Kingdom Hepatitis A Vaccine Sales, by Route of Administration K Unit (2021-2026)
  • Table 460. Netherlands Hepatitis A Vaccine Sales, by Type K Unit (2021-2026)
  • Table 461. Netherlands Hepatitis A Vaccine Sales, by Application K Unit (2021-2026)
  • Table 462. Netherlands Hepatitis A Vaccine Sales, by Patient Type K Unit (2021-2026)
  • Table 463. Netherlands Hepatitis A Vaccine Sales, by Route of Administration K Unit (2021-2026)
  • Table 464. Rest of Europe Hepatitis A Vaccine Sales, by Type K Unit (2021-2026)
  • Table 465. Rest of Europe Hepatitis A Vaccine Sales, by Application K Unit (2021-2026)
  • Table 466. Rest of Europe Hepatitis A Vaccine Sales, by Patient Type K Unit (2021-2026)
  • Table 467. Rest of Europe Hepatitis A Vaccine Sales, by Route of Administration K Unit (2021-2026)
  • Table 468. MEA Hepatitis A Vaccine Sales, by Country K Unit (2021-2026)
  • Table 469. MEA Hepatitis A Vaccine Sales, by Type K Unit (2021-2026)
  • Table 470. MEA Hepatitis A Vaccine Sales, by Application K Unit (2021-2026)
  • Table 471. MEA Hepatitis A Vaccine Sales, by Patient Type K Unit (2021-2026)
  • Table 472. MEA Hepatitis A Vaccine Sales, by Route of Administration K Unit (2021-2026)
  • Table 473. Middle East Hepatitis A Vaccine Sales, by Type K Unit (2021-2026)
  • Table 474. Middle East Hepatitis A Vaccine Sales, by Application K Unit (2021-2026)
  • Table 475. Middle East Hepatitis A Vaccine Sales, by Patient Type K Unit (2021-2026)
  • Table 476. Middle East Hepatitis A Vaccine Sales, by Route of Administration K Unit (2021-2026)
  • Table 477. Africa Hepatitis A Vaccine Sales, by Type K Unit (2021-2026)
  • Table 478. Africa Hepatitis A Vaccine Sales, by Application K Unit (2021-2026)
  • Table 479. Africa Hepatitis A Vaccine Sales, by Patient Type K Unit (2021-2026)
  • Table 480. Africa Hepatitis A Vaccine Sales, by Route of Administration K Unit (2021-2026)
  • Table 481. North America Hepatitis A Vaccine Sales, by Country K Unit (2021-2026)
  • Table 482. North America Hepatitis A Vaccine Sales, by Type K Unit (2021-2026)
  • Table 483. North America Hepatitis A Vaccine Sales, by Application K Unit (2021-2026)
  • Table 484. North America Hepatitis A Vaccine Sales, by Patient Type K Unit (2021-2026)
  • Table 485. North America Hepatitis A Vaccine Sales, by Route of Administration K Unit (2021-2026)
  • Table 486. United States Hepatitis A Vaccine Sales, by Type K Unit (2021-2026)
  • Table 487. United States Hepatitis A Vaccine Sales, by Application K Unit (2021-2026)
  • Table 488. United States Hepatitis A Vaccine Sales, by Patient Type K Unit (2021-2026)
  • Table 489. United States Hepatitis A Vaccine Sales, by Route of Administration K Unit (2021-2026)
  • Table 490. Canada Hepatitis A Vaccine Sales, by Type K Unit (2021-2026)
  • Table 491. Canada Hepatitis A Vaccine Sales, by Application K Unit (2021-2026)
  • Table 492. Canada Hepatitis A Vaccine Sales, by Patient Type K Unit (2021-2026)
  • Table 493. Canada Hepatitis A Vaccine Sales, by Route of Administration K Unit (2021-2026)
  • Table 494. Mexico Hepatitis A Vaccine Sales, by Type K Unit (2021-2026)
  • Table 495. Mexico Hepatitis A Vaccine Sales, by Application K Unit (2021-2026)
  • Table 496. Mexico Hepatitis A Vaccine Sales, by Patient Type K Unit (2021-2026)
  • Table 497. Mexico Hepatitis A Vaccine Sales, by Route of Administration K Unit (2021-2026)
  • Table 498. Hepatitis A Vaccine: by Type(USD/Units)
  • Table 499. Research Programs/Design for This Report
  • Table 500. Key Data Information from Secondary Sources
  • Table 501. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Hepatitis A Vaccine: by Type USD Million (2015-2020)
  • Figure 5. Global Hepatitis A Vaccine: by Application USD Million (2015-2020)
  • Figure 6. Global Hepatitis A Vaccine: by Patient Type USD Million (2015-2020)
  • Figure 7. Global Hepatitis A Vaccine: by Route of Administration USD Million (2015-2020)
  • Figure 8. South America Hepatitis A Vaccine Share (%), by Country
  • Figure 9. Asia Pacific Hepatitis A Vaccine Share (%), by Country
  • Figure 10. Europe Hepatitis A Vaccine Share (%), by Country
  • Figure 11. MEA Hepatitis A Vaccine Share (%), by Country
  • Figure 12. North America Hepatitis A Vaccine Share (%), by Country
  • Figure 13. Global Hepatitis A Vaccine: by Type K Unit (2015-2020)
  • Figure 14. Global Hepatitis A Vaccine: by Application K Unit (2015-2020)
  • Figure 15. Global Hepatitis A Vaccine: by Patient Type K Unit (2015-2020)
  • Figure 16. Global Hepatitis A Vaccine: by Route of Administration K Unit (2015-2020)
  • Figure 17. South America Hepatitis A Vaccine Share (%), by Country
  • Figure 18. Asia Pacific Hepatitis A Vaccine Share (%), by Country
  • Figure 19. Europe Hepatitis A Vaccine Share (%), by Country
  • Figure 20. MEA Hepatitis A Vaccine Share (%), by Country
  • Figure 21. North America Hepatitis A Vaccine Share (%), by Country
  • Figure 22. Global Hepatitis A Vaccine: by Type USD/Units (2015-2020)
  • Figure 23. Global Hepatitis A Vaccine share by Players 2020 (%)
  • Figure 24. Global Hepatitis A Vaccine share by Players (Top 3) 2020(%)
  • Figure 25. Global Hepatitis A Vaccine share by Players (Top 5) 2020(%)
  • Figure 26. BCG Matrix for key Companies
  • Figure 27. GlaxoSmithKline (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 28. GlaxoSmithKline (United Kingdom) Revenue: by Geography 2020
  • Figure 29. Merck & Co. (United States) Revenue, Net Income and Gross profit
  • Figure 30. Merck & Co. (United States) Revenue: by Geography 2020
  • Figure 31. SANOFI PASTEUR S.A (France) Revenue, Net Income and Gross profit
  • Figure 32. SANOFI PASTEUR S.A (France) Revenue: by Geography 2020
  • Figure 33. Norvatis (Switzerland) Revenue, Net Income and Gross profit
  • Figure 34. Norvatis (Switzerland) Revenue: by Geography 2020
  • Figure 35. Johnson & Johnson (United States) Revenue, Net Income and Gross profit
  • Figure 36. Johnson & Johnson (United States) Revenue: by Geography 2020
  • Figure 37. China Academy of Medical Sciences (China) Revenue, Net Income and Gross profit
  • Figure 38. China Academy of Medical Sciences (China) Revenue: by Geography 2020
  • Figure 39. Sinovac Biotech Ltd. (China) Revenue, Net Income and Gross profit
  • Figure 40. Sinovac Biotech Ltd. (China) Revenue: by Geography 2020
  • Figure 41. Walvax Biotechnology Co. (China) Revenue, Net Income and Gross profit
  • Figure 42. Walvax Biotechnology Co. (China) Revenue: by Geography 2020
  • Figure 43. Global Hepatitis A Vaccine: by Type USD Million (2021-2026)
  • Figure 44. Global Hepatitis A Vaccine: by Application USD Million (2021-2026)
  • Figure 45. Global Hepatitis A Vaccine: by Patient Type USD Million (2021-2026)
  • Figure 46. Global Hepatitis A Vaccine: by Route of Administration USD Million (2021-2026)
  • Figure 47. South America Hepatitis A Vaccine Share (%), by Country
  • Figure 48. Asia Pacific Hepatitis A Vaccine Share (%), by Country
  • Figure 49. Europe Hepatitis A Vaccine Share (%), by Country
  • Figure 50. MEA Hepatitis A Vaccine Share (%), by Country
  • Figure 51. North America Hepatitis A Vaccine Share (%), by Country
  • Figure 52. Global Hepatitis A Vaccine: by Type K Unit (2021-2026)
  • Figure 53. Global Hepatitis A Vaccine: by Application K Unit (2021-2026)
  • Figure 54. Global Hepatitis A Vaccine: by Patient Type K Unit (2021-2026)
  • Figure 55. Global Hepatitis A Vaccine: by Route of Administration K Unit (2021-2026)
  • Figure 56. South America Hepatitis A Vaccine Share (%), by Country
  • Figure 57. Asia Pacific Hepatitis A Vaccine Share (%), by Country
  • Figure 58. Europe Hepatitis A Vaccine Share (%), by Country
  • Figure 59. MEA Hepatitis A Vaccine Share (%), by Country
  • Figure 60. North America Hepatitis A Vaccine Share (%), by Country
  • Figure 61. Global Hepatitis A Vaccine: by Type USD/Units (2021-2026)
List of companies from research coverage that are profiled in the study
  • GlaxoSmithKline (United Kingdom)
  • Merck & Co. (United States)
  • SANOFI PASTEUR S.A (France)
  • Norvatis (Switzerland)
  • Johnson & Johnson (United States)
  • China Academy of Medical Sciences (China)
  • Sinovac Biotech Ltd. (China)
  • Walvax Biotechnology Co. (China)
Select User Access Type

Key Highlights of Report


Jan 2022 204 Pages 72 Tables Base Year: 2021 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Hepatitis A Vaccine review Quantitative research analysis
Global Hepatitis A Vaccine review Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The Hepatitis A Vaccine market is expected to see a CAGR of % during projected year 2020 to 2026.
Top performing companies in the Global Hepatitis A Vaccine market are GlaxoSmithKline (United Kingdom), Merck & Co. (United States), SANOFI PASTEUR S.A (France), Norvatis (Switzerland), Johnson & Johnson (United States), China Academy of Medical Sciences (China), Sinovac Biotech Ltd. (China) and Walvax Biotechnology Co. (China), to name a few.
"Initiatives to Enhance Vaccine R&D by Key Market Players" is seen as one of major influencing trends for Hepatitis A Vaccine Market during projected period 2020-2026.

Know More About Global Hepatitis A Vaccine review Report?

Have a Query? Click Here

Other Related Reports

Anti-Suicide Drug Comprehensive Study by Type (Anti-Depressants and Anti-Anxiety Drugs, Anti-Psychotic Drugs, NMDA Antagonist, Antibiotic Analog), Application (Hospital, Clinic, Home Use), Distributi...
$ 3800
Actinic Keratosis Drugs Comprehensive Study by Type (Nucleoside metabolic inhibitors, Immunomodulators, Photosensitizing agents, NSAIDs), Way of Intake (Tablets, Cream, Other), End User (Hospitals, C...
$ 3450
Medium-chain Triglycerides Comprehensive Study by Type (Caprylic Acid, Capric Acid, Lauric Acid, Caproic Acid), Application (Nutritional Diet, Personal Care, Pharmaceuticals, Sports Drinks, Infant Fo...
$ 3450
Antacid Tablet Comprehensive Study by Type (Ca-based, Mg-based, Mixed), Application (In-Patient, Out-Patient), Distribution Chanel (Hospital Pharmacies, Retail Pharmacies, Others) Players and Region ...
$ 3500
Neisseria meningitidis Infections Drug Comprehensive Study by Type (Penicillin, Ampicillin, Ceftriaxone), End-users (Hospital, Clinic, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmac...
$ 3350
Cholera Vaccine Comprehensive Study by Type (Shanchol, Dukoral, Vaxchora, Others), End-users (Hospital, Research & Academic Laboratories, Pharmaceutical & Biotechnology Companies, Others), Serogroup ...
$ 3350